TY - JOUR
T1 - Leukocytes and neurogenic inflammation
AU - Grant, Andrew
PY - 2001/8/31
Y1 - 2001/8/31
N2 - Neurogenic inflammation is caused by the release of substance P and CGRP from sensory nerves, which stimulates microvascular plasma extravasation and vasodilatation. There is now an increasing body of evidence supporting a role for these neuropeptides in the control of the immune response, in addition to their local inflammatory effects. Indirectly, their ability to increase blood flow allows them to potentiate immunocyte accumulation. They are also able to directly affect immunocytes through cell surface receptors. Substance P has a general stimulatory role, activating immunocytes and enhancing their activities (e.g. cytokine and antibody production). CGRP plays a more subdued role, tailoring the immune response to particular pathogens. Recent evidence suggests that some immunocytes may even be able to synthesise and release neuropeptides. Overall, an increasingly complex system of neuropeptide control of the immune system is apparent, potentially providing novel therapeutic targets
AB - Neurogenic inflammation is caused by the release of substance P and CGRP from sensory nerves, which stimulates microvascular plasma extravasation and vasodilatation. There is now an increasing body of evidence supporting a role for these neuropeptides in the control of the immune response, in addition to their local inflammatory effects. Indirectly, their ability to increase blood flow allows them to potentiate immunocyte accumulation. They are also able to directly affect immunocytes through cell surface receptors. Substance P has a general stimulatory role, activating immunocytes and enhancing their activities (e.g. cytokine and antibody production). CGRP plays a more subdued role, tailoring the immune response to particular pathogens. Recent evidence suggests that some immunocytes may even be able to synthesise and release neuropeptides. Overall, an increasingly complex system of neuropeptide control of the immune system is apparent, potentially providing novel therapeutic targets
KW - CGRP
KW - Lymphocyte
KW - Macrophage
KW - Neurogenic inflammation
KW - Substance P
UR - https://kings-uat.elsevierpure.com/portal/en/publications/1276c9f0-9b8c-4c68-9a95-afc80949616b
U2 - 10.1163/156856001320290660
DO - 10.1163/156856001320290660
M3 - Article (journal)
SN - 0925-4692
VL - 9
SP - 403
EP - 420
JO - Inflammopharmacology
JF - Inflammopharmacology
IS - 4
ER -